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Clinical Implications:  For patients who report fluoroquinolone allergy, we suggest specific 43 
restrictive intradermal skin test criteria are useful to identify those with true anaphylaxis 44 
as well as those where drug challenge can be safely applied. 45 
 46 
Fluoroquinolones (FQ) are the most frequently reported non-beta-lactam antibiotic allergy.1  The 47 
basic FQ structure is a bicyclic skeleton and can be classified by generation, with later 48 
generations correlating with broader gram-positive and anaerobic antimicrobial spectrum in 49 
particular.1 Interpretation of hypersensitivity reactions to FQare likely complicated by non-IgE 50 
mediated reactions since all FQ are small molecule ligands for the mast cell G-protein coupled 51 
receptor MRGPRX2 and have been shown to lead to direct mast cell activation in both in vitro 52 
models with the human MRGPRX2 receptor and murine models.2  Further, it is suspected that 53 
patients with true IgE-mediated allergy may have sel ctive FQ reactivity rather than generalized 54 
positivity on skin testing or oral challenge, as habeen described in several cases of lack of 55 
complete cross-reactivity between FQ and in particular tolerance of alternative FQ in patients 56 
with moxifloxacin hypersensitivity reactions.3  When expert consensus criteria for skin testing 57 
have been applied to FQ, utility has been limited by high-false positive rates due to non-specific 58 
mast cell activation. Uyttebroek et al. found positive moxifloxacin intradermal testing (IDT) in 59 
10/14 moxifloxacin allergic patients (2 at 0.0016 mg/ L; 2 at 0.016 mg/mL; 6 at 0.16 mg/mL) 60 
and in 12/16 moxifloxacin tolerant controls tested (2 at 0.016 mg/mL; 12 at 0.16 mg/mL).4  Non-61 
irritating concentrations of FQ IDT have been proposed, Chang et al. suggesting 0.005 mg/mL 62 
(ciprofloxacin, levofloxacin, moxifloxacin).3  Therefore, we present a newly proposed criteria for 63 
defining a positive FQ IDT that is founded in an understanding of non-specific mast cell 64 









new criteria in conjunction with oral challenge (OC) to an index or other FQ in adults who had a 66 
history of reacting to one or more FQ, and their subsequent tolerance of future FQ treatment. 67 
 68 
Our study presents a retrospective cohort study done under institutional review board (IRB) 69 
approved protocols from Vanderbilt University Medical Center (VUMC), IRB #161455.  70 
Between May 2015 and October 2019, 163 sequential patients with history-based past 71 
immediate, immediate-type, non-severe delayed or unknown reactions to one or more FQ with 72 
ongoing avoidance of FQ underwent IDT followed by selective OC in a dedicated outpatient 73 
drug allergy clinic at VUMC.  Patients with any history of a severe delayed immune mediated 74 
reaction, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, drug rash with 75 
eosinophilia and systemic symptoms, acute generalizd exanthematous pustulosis, or drug 76 
induced nephritis or hepatitis, were excluded.  In patients presenting for assessment of FQ 77 
allergy with a concurrent history of beta-lactam allergy and/or sulfa antibiotic allergy, de-78 
labeling to beta-lactams and sulfa antibiotics was the priority based on patient need, 79 
antimicrobial stewardship by referring infectious di eases physicians, and use of a safe and 80 
efficacious strategy to evaluate non-severe delayed reactions to sulfa antibiotics.5 Following 81 
successful de-labeling to beta-lactams and sulfa-antibiotics, patients had full assessment of FQ 82 
allergy if they had a potential future need.  Histamine was performed by skin prick at a 83 
concentration of 0.1 mg/mL. IDT to ciprofloxacin, levofloxacin, and moxifloxacin was 84 
performed — by European Network on Drug Allergy (ENDA) standardized technique — at 85 
concentrations of 0.025 mg/mL and 0.005 mg/mL, followed by single dose OC to the index FQ 86 
or other FQ (levofloxacin 250 mg, ciprofloxacin 250 mg, moxifloxacin 200 mg).6 A 200 mg dose 87 









success was defined by the absence of any symptoms during an observed 2 hour challenge 89 
period.  Patients were called by phone 24 hours after oral challenge to follow-up on any possible 90 
delayed reactions.  Oral challenge success resulted in the removal of FQ allergy or revision to 91 
confirm tolerance of an alternative FQ and patient education that FQ could now be used in their 92 
clinical care as appropriate.  We evaluated selected, urrently used expert consensus criteria for 93 
positive IDT: criteria #1: FQ wheal ≥ saline wheal + 3 mm; criteria #2: FQ wheal ≥ saline wheal 94 
+ 3 mm and flare present; criteria #3: FQ wheal ≥ 5mm and flare > wheal and compared these to 95 
our proposed criteria #4 for positive IDT: specific FQ flare at 0.025 mg/mL ≥ histamine flare, 96 
specific FQ flare ≥ 5 mm at 0.005 mg/mL, and no flare ≥ 5 mm for either of the other 2 FQ at 97 
0.005 mg/mL.  Criteria #1 is based on the “Drug allergy: an updated practice parameter” 98 
criteria.7  Criteria #2 is based on the ENDA criteria.8  Criteria #3 is derived from a currently used 99 
interpretation for a positive skin test in penicilln allergy.9  Criteria #4 was developed and refined 100 
during routine clinical care in an attempt to codify and apply retrospectively a criteria that 101 
encompassed the observation that non-specific wheal without flare frequently occurs to multiple 102 
skin tested FQ in patients — that would otherwise be positive by currently accepted skin testing 103 
guidelines —  who then go on to tolerate FQ oral chllenge.  Our hypothesis for this observation 104 
is that true IgE mediated FQ allergy is uncommon relative to non-IgE mediated reactions and 105 
that the majority of FQ reactions are likely a result of an off target, class pharmacologic effect 106 
via MRGPRX2 leading to non-IgE mediated mast cell activ tion.  An off target class-wide 107 
“pseudoallergy” effect mediated through a pharmacological interaction with MRGPRX2 rather 108 
than an IgE mechanism, is similar conceptually to what is observed in reactions associated with 109 
non-steroidal anti-inflammatory drugs (NSAIDs).  With NSAIDs true IgE-mediated reactions 110 









“pseudoallergic” reactions are pharmacologically mediated, related to inhibition of 112 
cyclooxygenase 1, and associated more broadly across all non-selective NSAIDs and aspirin. 113 
Unlike IgE-mediated reactions, which do not have tru  dose dependency, these pharmacological 114 
reactions that result from non-covalent interactions with an off-target receptor do vary based on 115 
dose, the kinetics of how the drug is administered (e.g. speed of infusion) and dosing with 116 
concurrent medications that have similar properties (e.g. vancomycin, neuromuscular blocking 117 
agents and opioids).  Study data were collected and managed using REDCap electronic data 118 
capture tools hosted at VUMC.  Analysis of IDT result  was performed with R (R Core Team 119 
2019). 120 
 121 
Charts were reviewed for patient demographics, timebetween index reaction and challenge, 122 
index reaction history (immediate within 1 hour, immediate-type within 1 to 36 hours, delayed 123 
greater than 36 hours or unknown timing of symptoms from first dose), indication for consult, 124 
co-morbidities, nature of initial label (ciprofloxacin, levofloxacin, moxifloxacin, or multiple FQ), 125 
total number of drug allergy labels, total number of antibiotic allergy labels, specific antibiotic 126 
allergy labels (penicillins, cephalosporins, and sulfa antibiotics), and history of allergy to drugs 127 
with implicated non-IgE mechanisms (vancomycin, radiocontrast, opioids, and neuromuscular 128 
blocking agents).  Like FQ, the drugs reviewed with implicated non-IgE mechanisms can also 129 
have IgE-mediated mechanisms.  Follow-up assessment to determine tolerance of any 130 
subsequent FQ treatments was performed by chart review.  131 
 132 
The demographic and clinical characteristics of the 163 patients are described in Table 1.  Index 133 









and 5 unknown.  Of the 136 patients with immediate or immediate-type index reactions, 31 135 
patients reported anaphylaxis or multisystem involvement compatible with anaphylaxis but not 136 
clearly defined as such on chart review.  The labeled FQ for patients included 58 ciprofloxacin-137 
only, 53 levofloxacin-only, 13 moxifloxacin-only, and 39 to ≥ 2 FQ (33 ciprofloxacin labels, 36 138 
levofloxacin labels, and 6 moxifloxacin labels).  For these 163 patients, the median total number 139 
of antibiotic allergy labels was 5 [IQR 3, 7] and 144/163 (88%) were evaluated for at least one 140 
additional antibiotic allergy besides FQ (Table 1).  84/163 (52%) patients reported an allergy to 141 
other drugs where a non-IgE mediated mechanism for ast cell degranulation has been reported.   142 
 143 
Of 163 patients, 96 (59%) were positive by criteria #1, 53 (33%) by criteria #2, 36 (22%) by 144 
criteria #3 at either 0.005 mg/mL or 0.025 mg/mL for at least 1 FQ (Table E1 available in this 145 
article’s Online Repository at www.jaci-inpractice.org).  If the 163 patients were restricted to 146 
only the 0.005 mg/mL concentration, 73 (45%) were positive by criteria #1, 19 (12%) by criteria 147 
#2, 13 (8%) by criteria #3 for at least 1 FQ.  By contrast, only 4/163 (2%) patients had positive 148 
IDT by proposed criteria #4. The 4 positive IDT patien s by criteria #4 all had an immediate, 149 
anaphylactic index reaction history, were IDT positive to their index label FQ (2 moxifloxacin, 1 150 
levofloxacin, and 1 ciprofloxacin), presented for evaluation within 1 year of their index reaction, 151 
and did not have any co-existing history of allergy to drugs implicated in non-IgE mediated mast 152 
cell activation. Of these 4 patients, 2 underwent and tolerated oral challenge to a skin-test 153 
negative FQ and the other 2 did not undergo oral chllenge due to time constraints related to 154 











Of the 159 patients with negative IDT by criteria #4, 82/159 (52%) underwent OC and 82/82 (21 158 
immediate, 47 immediate-type, 13 non-severe delayed, an  1 unknown index reaction history; 159 
100%) were de-labeled to their index FQ or an alternative FQ based on lack of an immediate or 160 
delayed reaction to single dose FQ (Figure 1).  161 
 162 
The other 77/159 patients with negative IDT by criteria by #4 did not undergo OC as a result of 163 
time constraints in clinic due to our prioritized tes ing of beta-lactam and sulfa allergies first.  All 164 
of these 77 patients — if they were to return to clini  in the future — would qualify for OC to 165 
FQ.  All patients who had an immediate or perceived high future need for a FQ underwent FQ 166 
ingestion challenge.  No delayed challenge reactions or delayed positive skin tests were reported. 167 
 168 
There were 68 patients with an immediate or immediat -type reaction history who underwent 169 
OC, 15 of whom reported anaphylaxis or multisystem involvement compatible with anaphylaxis 170 
but not clearly defined as such on chart review.  Of the 64 patients who underwent OC to their 171 
index FQ, 30 were to ciprofloxacin, 17 to levofloxacin, 2 to moxifloxacin, and 15 to at least 1 172 
index FQ in patients with multiple FQ allergy history (Table E2, available in this article’s 173 
Online Repository at www.jaci-inpractice.org).  There were 18 additional patients who 174 
underwent OC to an alternative FQ earlier on in the development of this FQ testing strategy due 175 
to a cautious evolution of our routine clinical care toward direct challenge with the implicated 176 
agent.  Of these 18 patients, 4 reported an index reaction history of anaphylaxis or multisystem 177 
involvement compatible with anaphylaxis and 2 reported an immediate reaction consisting of 178 
urticaria.  Of these 82 patients who underwent OC, 47/82 (57%) would have been deemed 179 









mg/mL or 0.025 mg/mL for at least 1 FQ.  Of the 82 patients with a negative OC, 23 (28%) 181 
patients were subsequently treated with a multiple dose therapeutic FQ course (12/23 to an index 182 
FQ; 7 levofloxacin, 5 ciprofloxacin), and all were tolerated uneventfully (Table E2, available in 183 
this article’s Online Repository at www.jaci-inpractice.org). 184 
 185 
Interpretation of hypersensitivity skin testing to FQ is likely complicated by non-IgE mediated 186 
reactions secondary to direct FQ mast cell activation via the G-protein coupled receptor 187 
MRGPRX2 that has been demonstrated by the mouse homolog MRGPRB2 and in vitro studies 188 
with the human receptor MRGPRX2.2  We observed that from 13/163 (8%) to 73/163 (45%) 189 
patients in our cohort had skin testing that would have been deemed as a positive test under 190 
current, expert consensus criteria at the 0.005 mg/mL concentration for interpretation of 191 
immediate IDT.  Under our proposed criteria, however, only 4 (2%) patients had a FQ specific 192 
positive IDT, and all 4 were specific to the single drug that was implicated in the original 193 
reaction.  Importantly, there were no cases of patients with positive oral challenge reactions who 194 
had an IDT negative on criteria #4 that were positive on criteria #1, #2, or #3. 82 FQ IDT 195 
negative patients by our proposed criteria were ablto tolerate challenge without any observed 196 
reactions, including from 27/82 (29%) to 47/82 (57%) who would have been deemed as having 197 
positive IDT under current, expert consensus criteria.  A limitation of our retrospective cohort 198 
design is that we were not able to capture the rate of minor, non-allergic symptoms during oral 199 
challenge that self-resolved without treatment. Ourlack of observation of any significant 200 
reactions on oral challenge may be the result of: challenge dose not high enough to elucidate 201 
non-IgE mediated reactions; inclusion of patients with index reactions inconsistent with an 202 









(median 8 years). While moxifloxacin is associated with the majority of anaphylaxis to FQ, it is 204 
not as commonly used in the United States as ciprofloxacin and levofloxacin and only accounted 205 
for 19/199 (10%) FQ labels in our study.1 Our results need to be validated in a separate and 206 
ideally multicenter population sample using skin testing and oral challenges to strengthen the 207 
case for using these modified criteria.   208 
 209 
In our population of patients with a potential immediate FQ allergy, we have started to 210 
characterize two phenotypes. The most prevalent of these is patients who likely have non-IgE 211 
mediated mast cell activation who tolerate challenges to FQ and are commonly labeled with 212 
reactions to drugs that also cause non-IgE mediated mast cell activation.  Much less common are 213 
patients with a clinical presentation consistent with anaphylaxis with true IgE-mediated reactions 214 
to FQ whose reactions are typically selective for a particular FQ and do not have multiple drug 215 
allergy labels, and in particular drug allergy labels that include other drugs likely to associate 216 
with non-IgE mediated mast cell activation such as v ncomycin and opioids.  In the typical 217 
outpatient allergy clinical setting, we believe that our proposed criteria may be able to help 218 
differentiate cases of non-IgE mediated mast cell activ tion prevalently associated with FQ and 219 
not a contraindication to future treatment, from the much less common and typically FQ 220 
selective IgE-mediated cases where the FQ should be avoided.  Hence, we can precisely target 221 
patients with IgE versus non-IgE mediated FQ allergy who would have drug-specific, dose-222 
independent skin test positivity at the 0.005 mg/mL concentration.  Furthermore, our results 223 
support the safety of the strategy of using a single rather than a graded challenge and using a 224 
lower dose (200 to 250 mg) of a FQ for OC that would be adequate to rule out a true IgE-225 









mediated mast cell activation. Use of the lower theap utic range of FQ in drug challenge is in 227 
keeping with other delabeling studies for antibiotic allergy.5, 9 It is, however, still possible for 228 
patients with a negative FQ oral challenge to experience a non-IgE mediated reaction in the 229 
future — as such reactions are stochastic to dose.  W  acknowledge that a higher evidence base 230 
is needed to support this but the practice of administering antihistamines to improve tolerance of 231 
non-IgE mediated reactions associated with FQ has biological plausibility, and we have 232 
recommended that patients take scheduled antihistamines.  Of 23 patients that were exposed to 233 
future treatment courses of FQ, 15 (65%) were taking a tihistamines throughout the course, and 234 
we postulate that this was beneficial in their tolerance. With regards to evaluating patients with a 235 
non-severe delayed reaction history, a negative single dose challenge to a FQ may not entirely 236 
exclude a potential delayed reaction as it may takesev ral doses to reappear, particularly with a 237 
less recent reaction, or may not be provoked with a 200 to 250 mg dose. 238 
 239 
In conclusion, others have previously questioned th utility of skin testing as a diagnostic 240 
modality for immediate reactions associated with FQ because of the high degree of non-IgE 241 
mediated mast cell activation that has impaired the ability to interpret skin testing by currently 242 
used criteria.  Our data is reassuring in suggesting that most patients with non-anaphylactic 243 
immediate histories such as urticaria will tolerate single dose 200 to 250 mg challenge with a FQ 244 
and further tolerate therapeutic courses of FQ.  Similar to other drugs when skin testing utility is 245 
unproven or not available to a clinician in patients who do not report a history of anaphylaxis, 246 
single or graded oral challenge to FQ may be safely pplied in the outpatient setting.  For 247 
patients whose histories are consistent with anaphyl xis, we propose that a distinct set of criteria 248 









should be excluded from a specific FQ but may tolerate an alternative one. We demonstrate a set 250 
of criteria that appear to safely identify patients who are eligible for challenge, many of whom 251 
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Figure Legends: 308 
Figure 1. Flowchart of the study. FQ, fluoroquinolone; IDT, intradermal testing 309 
a96/163 (59%) were IDT positive by criteria #1; 53/163 (33%) by criteria #2; and 36/163 (22%) 310 
by criteria #3 at either 0.005 mg/L or 0.025 mg/mL for at least 1 FQ 311 
b47/82 (57%) were positive by criteria #1; 27/82 (29%) by criteria #2; and 29/82 (35%) by 312 
criteria #3 at either 0.005 mg/L or 0.025 mg/mL for at least 1 FQ. For greater detail on index 313 
reaction type, severity, and FQ; oral challenge FQ;subsequent treatment FQ, please see Table 314 
E2 (available in this article’s Online Repository at ww.jaci-inpractice.org) 315 
cThese 77 patients did not undergo OC as a result of time constraints in clinic due to our 316 
prioritized testing of beta-lactam and sulfa allergi s first.  All of these 77 patients, if they were to 317 
return to clinic in the future, would qualify for FQ oral challenge. 318 
d30 were to ciprofloxacin, 17 to levofloxacin, 2 to moxifloxacin and 15 to at least 1 index FQ in 319 
patient with allergy history to ≥ 2 FQ. 320 
eThe 18 patients who underwent oral challenge to an alternative FQ did so earlier on in the 321 
development of this FQ testing strategy due to a cautious evolution of our routine clinical care.  322 
Of these 18 patients, 4 reported an index reaction history of anaphylaxis or multisystem 323 
























Table 1. Characteristics of patients who underwent fluoroquinolone intradermal testing and/or 
selective fluoroquinolone oral challenge  
 Total N (% total) or Median [IQR] 
Total no. of patients 163 
Age 61 [50, 70] 
Time since reaction in years (**n=107, with n=56 missing) 8 [1, 16] 
Sex 
    Female 





    White 
    Unknown 
    Black 
    Other 
 




Index reaction history 
    Immediate symptoms (< 1 hour) 
        Mild to moderate exanthem 
        Urticaria 
        Angioedema 
        Shortness of breath 
        Hypotension 
        Anaphylaxis 
    Immediate-type symptoms (1 to 36 hours) 
        Mild to moderate exanthem 
        Urticaria 
        Angioedema 
        Shortness of breath 
        Hypotension 
        Anaphylaxis 
    Non-severe delayed symptoms 


















Indication for Consult 
    Multi-drug allergy 
    Anticipated need for treatment and/or prophylaxis 





Total no. drug allergy labels 
    No. of antibiotic allergy labels 
        Penicillin allergy 
            Underwent testing 
                Label removed 
                    Subsequently treated after removal 
                Label not removed 
        Cephalosporin allergy 
            Underwent testing 
                Label removed or revisedb 
                    Subsequently treated after removal 
                Label not removed 
        Sulfa antibiotic allergy 
            Underwent testing 
                Label removed 
                    Subsequently treated after removal 
                Label not removed 
7 [5, 11] 
















History of allergy to a drug with an implicated non-IgE mechanism? 
    Yes 
        Opioid 
        Radiocontrast 
        Vancomycin 
        Neuromuscular blocking agent 









    Hematologic or oncologic malignancy 
    Diabetes 
    Recurrent sinusitis 
    Recurrent UTI 
    CVID 
    Cystic fibrosis 
    MRSA 
    Pre-solid organ or bone marrow transplant 
    Solid organ transplant  




















    Bone marrow transplant 1 
Nature of initial label 
    Ciprofloxacin-only 
    Levofloxacin-only 
    Moxifloxacin-only 
    Multiple fluoroquinolones 
        Ciprofloxacin label 
        Levofloxacin label 









Type of challenge (selected/dependent upon index reaction history) 
    Ciprofloxacin 
    Levofloxacin 





aEither anaphylaxis or multisystem involvement compatible with anaphylaxis but not clearly defined as such on chart review 340 
bLabel may have been revised to demonstrate safety for a non-cross reactive R-side chain cephalosporin rather than removal of index label due to 341 












Result of oral challenge
Type of oral challenge
Oral challenge
Results of IDT by criteria #4
Sequential patients with immediate, 
immediate-type, delayed or unknown 



















































Table E1. IDT results by FQ and concentration used for criteria #1, criteria #2, criteria #3, and criteria #4 and if underwent oral challenge to IDT positive FQ in 163 patientsa 
 
Abbreviations: FQ = fluoroquinolone; IDT = intradermal test 
a82 of 159 patients with negative IDT by criteria #4 underwent oral challenge to a total 85 FQ doses (15 patients labeled to ≥ 2 FQ). 2 of 4 patients with positive IDT by critera #4 for a specific FQ 
underwent oral challenge to an IDT negative FQ. No immediate or delayed reactions were observed in patents that underwent IDT and FQ oral challenge.  
bBased on the “Drug allergy: an updated practice parameter” (Ann Allergy Asthma Immunol. 2010) 
cBased on the the European Network on Drug Allergy (ENDA) criteria (Brockow K et al. Allergy. 2013) 
dBased on currently used interpretation for a positive skin test in penicillin allergy (Shenoy ES et al. JAMA. 2019) 
eStudy proposed criteria developed during routine clinical care and applied retrospectively based on observation that non-specific wheal without flare frequ ntly occurs in patients with suspected non-





• FQ wheal ≥   




• FQ wheal ≥  
saline wheal + 3mm 
• Flare present 
Criteria #3d 
 
• FQ wheal ≥ 5 mm 
• Flare > wheal 
Criteria #4e 
 
• Specific FQ flare at 0.025 
mg/mL ≥ histamine flare 
• Specific FQ flare ≥ 5 mm at 
0.005 mg/mL 
• No flare ≥ 5 mm for either of the 




























































































































Table E2. Index FQ and reaction, oral challenge FQ, and subsequent treatment FQ for the 82 patients with negative intradermal testing by proposed criteria #4 who underwent oral challenge 
 
  Oral 
Challenge FQ Subsequent Treatment 
Oral 
Challenge FQ Subsequent Treatment 
Oral 




Total number of 
labelsa 
  • Total oral 
challenged (OC)b 
     • Total subsequent        













  • 50 OC 
     • 14 Treatments 
Immediated 6 
   • 0 
0 0 0 
4 
   • 1 
0 0 0 0 0 0 0 
Immediate-typee 30 
   • 6 
5 
   • 2 
5 
   • 0 
0 
4 
   • 1 
0 
2 
   • 0 
0 0 0 0 0 
Delayed 2 0 1 0 3 0 1 0 0 0 0 0 




  • 40 OC 
     • 13 Treatments  
Immediate 6 
   • 2 
0 0 0 
7 
   • 1 
2 
   • 0 
2 
   • 0 
0 0 0 0 0 
Immediate-type 8  
   • 3 
3 
   • 2 
1 
   • 0 
0 
12 
   • 2 
1 
   • 0 
3 
   • 0 
0 0 0 0 0 
Delayed 2 0 0 0 5 1 1 0 0 0 0 0 




  • 10 OC 
     • 1 Treatment  
Immediate 3  
   • 2 
1 
   • 0 
0 0 
1 
   • 1 
0 0 0 0 0 0 0 
Immediate-type 2  
   • 1 
0 0 0 0 0 0 0 
2 
   • 0 
0 0 0 
Delayed 0 0 0 0 2 0 0 0 0 0 0 0 
Unknown 0 0 0 0 0 0 0 0 0 0 0 0 
Abbreviations: C = ciprofloxacin FQ = fluoroquinolone; L = levofloxacin; M = moxifloxacin; OC = oral challenge 
aOf the 163 patients, 39 patients carried labels for ≥ 2 FQ, bringing total labels to 199. 
bOf the 82 patients who underwent oral challenge, 15 patients carried labels for ≥ 2 FQ.  In total, there were 85 oral challenge doses administered and, in this table, patients with multiple FQ labels are 
counted for each of their index fluoroquinolone labels, bringing the total OC represented in this table to 100.   
cOf the 23 patients that underwent subsequent treatment, 6 patients carried labels for ≥ 2 FQ, and in this table, patients with multiple FQlabels are counted for each of their index FQ labels, bringing the 
total subsequent treatments represented in this table to 28. 
dSymptoms occurring within 1 hour of first dose 
eSymptoms occurring within 1 to 36 hours of first dose 
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